

15 July 2024

**Privatisation by way of merger**

**Disclosure of dealings in the shares of Shanghai Henlius Biotech, Inc. – H shares**

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

<b>Party</b>	<b>Date</b>	<b>Purchase / Sale</b>	<b>Number of shares</b>	<b>Price per share</b>	<b>Resultant balance (including those of any person with whom there is an agreement or understanding)</b>	<b>Percentage of class (including those of any person with whom there is an agreement or understanding)</b>
Lin Lijun	8 July 2024	Purchase	645,200	\$22.8237	9,155,732	5.6023%
		Purchase	467,300	\$22.8279	8,510,532	5.2075%

End

Note:

Lin Lijun is a Class (6) associate connected with the Offeree company.

Dealings were made for its own account.



Mr. Lin Lijun, through controlled corporations, is interested in 4,200,000 domestic shares of Shanghai Henlius Biotech, Inc. (the Company), representing approximately 1.11 per cent of the total issued domestic shares of the Company. On 8 July 2024, Mr. Lin Lijun acquired 467,300 and 645,200 H shares of the Company, respectively, through Golden Valley Value Select Master Fund and Golden Valley Global Limited, respectively.

This form was received by the Executive on 15 July 2024.